THTasuku Hanajima

Tasuku Hanajima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tasuku Hanajima has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polymyxin B Hemoperfusion for Patients With Septic Shock Requiring High-Dose Norepinephrine: A Multicenter Prospective Cohort Study

    by Yu Kawazoe, Kyohei Miyamoto, Noriko Miyagawa, Yoshinori Ohta, Hitoshi Yamamura, Takuya Kimura, Yukitoshi Toyoda, Michihito Kyo, Tetsuya Sato, Masashi Kinjo, et al.

    IMPORTANCE: Polymyxin B hemoperfusion (PMX-HP) is a potential therapeutic option for sepsis; however, its clinical effects remain unclear. OBJECTIVE: We explored the association between PMX-HP and clinical outcomes in patients in ICUs. DESIGN, SETTING, AND PARTICIPANTS: This is a multicenter prospective cohort study conducted in 20 ICUs in Japan between 2020 and 2022. Patients with septic shock requiring high-dose norepinephrine (≥ 0.2 µg/kg/min) were included. MAIN OUTCOMES AND MEASURES: We compared patient characteristics and outcomes between those who received PMX-HP (PMX group) and those who did not (non-PMX group). A primary outcome was 28-day mortality, with secondary outcomes including changes in mean arterial pressure (MAP) and vasoactive-inotropic score over time in the initial 48 hours, 28-day vasopressor-free days, and 90-day mortality rate. RESULTS: Among 309 patients, 175 (56.6%) were males, with a median age of 72 years and an Acute Physiology and Chronic Health Evaluation II (APACHE II) score of 26. Overall, 82 patients underwent PMX-HP. The PMX and non-PMX groups had similar median ages (71 vs. 73 yr) and APACHE II scores (26 vs. 27). The median PMX-HP duration was 1016 minutes. The 28-day mortality was similar between the groups (PMX group: 17.1%, non-PMX group: 18.9%, p = 0.71), with an adjusted hazard ratio of 0.88 (95% CI, 0.46–1.68). MAP was maintained at a higher level with low-dose vasopressor from 8 to 32 hours following admission in the PMX group. The PMX group had fewer 28-day ICU-free days (16 vs. 18, p = 0.026). The 90-day mortality rate was similar between the groups (PMX group, 23.5%; non-PMX group, 27.1%; p = 0.62). CONCLUSIONS AND RELEVANCE: PMX-HP was not associated with the 28-day mortality improvement but was associated with higher MAP and lower vasopressor use for 8–32 hours of admission. Our findings suggested that PMX-HP requires careful adaptation.


  • Open Access

    Transcatheter arterial embolization for severe blunt liver injury in hemodynamically unstable patients: a 15-year retrospective study

    by Satoshi Tamura, Takaaki Maruhashi, Fumie Kashimi, Yutaro Kurihara, Tomonari Masuda, Tasuku Hanajima, Yuichi Kataoka, Yasushi Asari

    Background: Transcatheter arterial embolization (TAE) is the first-line nonsurgical treatment for severe blunt liver injury in patients, whereas operative management (OM) is recommended for hemodynamically unstable patients. This study investigated the comparative efficacy of TAE in hemodynamically unstable patients who responded to initial infusion therapy. Methods: This retrospective study enrolled patients with severe blunt liver injuries, which were of grades III–V according to the American Association for the Surgery of Trauma Organ Injury Scale (OIS). Patients who responded to initial infusion therapy underwent computed tomography to determine the treatment plan. A shock index > 1, despite undergoing initial infusion therapy, was defined as hemodynamic instability. We compared the clinical outcomes and mortality rates between patients who received OM and those who underwent TAE. Results: Sixty-two patients were included (eight and 54 who underwent OM and TAE, respectively; mean injury severity score, 26.6). The overall in-hospital mortality rate was 6% (13% OM vs. 6% TAE, p = 0.50), and the hemodynamic instability was 35% (88% OM vs. 28% TAE, p < 0.01). Hemodynamically unstable patients who underwent TAE had 7% in-hospital mortality and 7% clinical failure. Logistic regression analysis showed that the treatment choice was not a predictor of outcome, whereas hemodynamic instability was an independent predictor of intensive care unit stay ≥7 days (odds ratio [OR], 3.80; p = 0.05) and massive blood transfusion (OR, 7.25; p = 0.01); OIS grades IV–V were predictors of complications (OR, 6.61; p < 0.01). Conclusions: TAE in hemodynamically unstable patients who responded to initial infusion therapy to some extent has acceptable in-hospital mortality and clinical failure rates. Hemodynamic instability and OIS, but not treatment choice, affected the clinical outcomes.


  • Open Access

    Usefulness of lavage and drainage using video-assisted thoracoscopic surgery for Boerhaave’s syndrome: a retrospective analysis

    by Tasuku Hanajima, Yuichi Kataoka, Tomonari Masuda, Yasushi Asari

    Background: Boerhaave’s syndrome has a high mortality rate due to respiratory failure, septic shock, and multiple organ failure. We had previously carried out primary repair with laparotomy and postoperative computed tomography-guided drainage for mediastinal abscess and empyema. However, this treatment prolonged mechanical ventilator days and length of intensive care unit stay. Therefore, we decided to carry out primary repair with laparotomy and add lavage and drainage using video-assisted thoracoscopic surgery. Methods: From April 2004 to September 2018, 18 patients with Boerhaave’s syndrome were treated; 6 patients treated conservatively were excluded. Thus, 12 patients who underwent surgical treatment were divided into the computed tomography-guided drainage group (D group) (6 patients) and the lavage and drainage using video-assisted thoracoscopic surgery group (VATS group) (6 patients), and the two groups were retrospectively compared. Results: The VATS group had significantly longer operation time than the D group {359 [328, 387] vs. 220 [155, 235] min, P=0.004}, but the ventilator-free days (VFDs) were significantly extended {24 [21, 24] vs. 10 [0, 17] days, P=0.02}, and the length of intensive care unit stay was significantly shortened {14 [8, 14] vs. 35 [29, 55] days, P=0.01}. Conclusions: Lavage and drainage using video-assisted thoracoscopic surgery is an effective surgical method for Boerhaave’s syndrome.


  • Hybrid treatment combining emergency surgery and intraoperative interventional radiology for severe trauma

    by Yuichi Kataoka, Hiroaki Minehara, Fumie Kashimi, Tasuku Hanajima, Tatsuhiro Yamaya, Hiroshi Nishimaki, Yasushi Asari